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Abstract
The disease course of human immunodeficiency virus (HIV) is often altered by existing or newly
acquired coinfections. Treatment or prevention of these concomitant infections often improves the
quality and duration of life of HIV-infected persons. The impact of helminth infections on infections
with HIV is less clear. However, HIV is frequently most problematic in areas where helminth
infections are common. In advance of the widespread distribution of drugs for elimination of
lymphatic filariasis, we assessed the prevalence of active Wuchereria bancrofti infection among
HIV-positive patients in Chennai, India at two time points separated by four years. We found that
the overall prevalence of W. bancrofti infections among HIV-positive persons was 5–9.5%, and there
were no quantitative differences in circulating filarial antigen levels between HIV-positive and HIV-
negative filarial-infected patients.
Introduction
The disease course of human immunodeficiency virus (HIV) is dependent on many factors,
including host, virus, treatment, and environment. Mechanisms delaying disease progression
are of primary importance. One such strategy is to address concomitant infections: from the
beginning of the HIV epidemic, HIV was recognized by a constellation of opportunistic
infections that accompany advanced disease. Through treatment and prevention of these non-
HIV diseases, life expectancies of HIV-infected persons are greatly prolonged, even without
specific antiretroviral treatments.
Coinfection with systemic helminths, in addition to causing morbidity on their own, may
contribute to an increased morbidity from HIV. An in vitro study demonstrated that peripheral
blood mononuclear cells from persons with actively filarial infections were more susceptible
to HIV infection than were the cells from the same persons after definitive treatment of their
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filarial infections.1 Moreover, a cross-sectional prevalence study in Tanzania showed that
people positive for circulating antigen of Wuchereria bancrofti were more likely to be HIV
positive than persons without filarial infections.2 Although intriguing and with potential
significance for HIV control programs in filarial-endemic areas, the implications of these
findings have yet to be determined.
Few studies have examined the burden of parasitic infections in HIV-infected persons, yet it
is likely to be as high or higher than that in the general population. The latest figures from the
World Health Organization estimate that 129 million persons worldwide are infected with W.
bancrofti, Brugia malayi, or B. timori, the major causative agents of lymphatic filariasis, that
3.5 billion persons are infected with intestinal helminths, and that there are 300–500 million
new cases of malaria per year. Most of this burden of disease is concentrated in countries where
HIV incidence and prevalence are greatest. In India, parasitic infections are endemic
throughout the country with the prevalence of hookworm infection ranging between 30% and
62% (in regions around Chennai); the prevalence of Strongyloides and Ascaris is lower.3 The
prevalence of lymphatic filariasis, a disease caused by the nematode W. bancrofti in southern
India, is estimated to be 6–20% on the basis of circulating filarial antigenemia.3
According to figures from the National AIDS Control Organization and the United Nations
Joint Program on HIV/AIDS,4 the estimated number of adults in India living with HIV/
acquired immunodeficiency syndrome in 2007 was 0.36% of the general population
(approximately 2.5 million people); the distribution is not uniform, with a higher prevalence
in the southern Indian states than in northern states. Prevalence rates among select groups, such
as commercial sex workers, persons who come to sexually transmitted disease clinics, and
intravenous drug users, are much higher and approach 10–30%.5 Use of antiretroviral drugs
in the public health system is expanding gradually in this population, with an estimated 100,000
persons (6–15% of the population qualifying for antiretroviral drugs) receiving the medications
at the end of 2006.6,7
In advance of mass drug administration for lymphatic filariasis and to ultimately assess the
impact of antifilarial treatment on HIV/filaria coinfection in India, we conducted two surveys
four years apart in serum samples of HIV-positive patients, looking for evidence of active
filarial infection. Our question was whether HIV-infected persons had a higher or lower
prevalence of filarial infection than HIV-negative patients in Chennai, Tamil Nadu, India.
Methods
The Institutional Review Boards of the National Institute of Allergy and Infectious Diseases
(Bethesda, MD), the Y. R. Gaitonde Centre for AIDS Research and Education, and the
Tuberculosis Research Center (both in Chennai, India) reviewed and approved this study. In
2000, 432 HIV-positive serum samples (and for comparison a group of HIV-negative sera from
voluntarily screened patients) from the HIV clinic at Y. R. Gaitonde Centre for AIDS Research
and Education were assessed for active filarial infection by detection of circulating filarial
antigen (CFA). In 2004, 200 HIV-positive sera from patients from the HIV clinic at the
Tuberculosis Research Center were tested. Samples from both clinics were well-characterized
stored sera from persons referred for HIV testing. The HIV-positive and HIV-negative samples
were from persons of the same socioeconomic status. Because samples were de-identified, no
information was available on age, sex, or other demographic information.
We used the W. bancrofti NOW® immunochromographic (ICT) antigen card test (Binax,
Portland, ME) to determine prevalence of filarial infection.8 To quantify antigen levels, ICT-
positive sera were analyzed using the W. bancrofti Og4C3 antigen-capture enzyme-linked
immunosorbent assay (TropBio, James Cook University, Townsville, Queensland, Australia)
Talaat et al. Page 2
Am J Trop Med Hyg. Author manuscript; available in PMC 2009 October 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
according to the manufacturer's instructions.9 No duplication of patients occurred between
2000 and 2004. Statistical analysis was done using the Mann-Whitney U test and StatView™
software (Abacus, London, United Kingdom).
Results
Of 432 HIV-positive patients screened in 2000, 21 (4.9%) were positive for filarial antigen by
the ICT card test. In 2004, 200 patient serum samples were screened, 19 of which were positive
by the ICT card test, resulting in an HIV/W. bancrofti coinfection prevalence of 9.5% (Figure
1A). Prevalence of W. bancrofti infection in HIV-positive persons did not differ statistically
from that of HIV-persons (7%, n = 99).
Because infection with W. bancrofti likely preceded the acquisition of HIV, we assessed
whether HIV infection influenced the level or burden of filarial infection. Thus, levels of W.
bancrofti circulating antigen were quantitated in both HIV-positive and HIV-negative persons.
When filarial-infected persons with or without HIV infections were assessed by quantitative
enzyme-linked immunosorbent assay for CAg of W. bancrofti, there was no statistically
significant (P = 0.07) difference in the level of filaria antigenemia in the two groups (Figure
1B). The geometric mean (range) CAg levels were 2,700 (217–21,080) units/mL in HIV-
positive persons and 3,211 (501–7,799) units/mL in HIV-negative persons.
Discussion
Controlling concomitant infections that may have a detrimental effect on infection with HIV
is imperative. Although infection with HIV will progress and definitive antiretroviral treatment
will be necessary, the precedence for postponing illness and death in HIV patients by
controlling concomitant infections has been well established in other coinfections. The impact
of parasitic infection, other than that with Toxoplasma gondii, on HIV has only recently been
examined. Many countries now considered epicenters of HIV transmission and disease are in
tropical and subtropical areas of the world where the burden of parasitic diseases remains highly
significant.
The interaction of helminth infections with HIV has not been completely clarified. The
dominance of type 2 cytokines present in persons with helminth infections has been postulated
to encourage HIV replication because immune control of HIV requires Th1-mediated
mechanisms. Some studies have shown that patients infected with HIV and concomitant
intestinal helminth infections have decreased viral loads upon treatment.10 Other studies have
shown that patients infected with HIV and helminths had higher CD4 cell counts, lower viral
loads, and higher CD4:CD8 ratios than did HIV-positive, helminth-negative patients. This
finding was also observed in those with concomitant hookworm infections.11 Coinfection with
hookworm was associated with a lower mortality rate in HIV-positive patients.12 Another
study demonstrated that hookworm-infected patients were less likely to become infected with
HIV than hookworm-negative patients.2
Few studies have examined the interaction of filarial infection with HIV. In two small studies
of coinfection with Onchocerca volvulus and HIV, those infected with HIV had more
significant onchocercal skin disease13 and were less likely to have antibodies in response to
onchocercal antigens.14 In vitro studies showed that peripheral blood mononuclear cells from
filarial-infected persons were more susceptible to HIV infection, and this susceptibility
decreased once the patients were treated for their filarial infection.1 One recent study that
examined the prevalence of HIV and parasitic coinfections in Tanzania found that filarial
antigen positivity was a positive predictor of HIV infection.2 When persons HIV positive and
CFA positive were compared with persons who were HIV-negative and CFA positive, there
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was no difference in levels of CFA. Presence of filarial antigen did not affect HIV viral load,
CD4 cell count, or CD4%.15 When a small subset of HIV-positive persons was treated with
diethylcarbamazine, 12 weeks after treatment there was a statistical difference in HIV viral
load between CFA-positive and CFA-negative volunteers.16 Both in vitro and in vivo findings,
if they can be shown to have wider applications, may have an impact on the Global Program
to Eliminate Lymphatic Filariasis, as well as the National HIV control programs.
We attempted to determine the coprevalence of HIV and filarial infection in an area where
filaria are endemic, and HIV is a growing problem. We found that the rate of filarial infection
is similar to that reported in the general population (6–10%). Moreover, at a quantitative level,
filarial antigenemia did not differ between HIV-positive and HIV-negative filarial infected
groups. Because of the mass drug administration programs to interrupt transmission of filarial
infections, it is important to know the effect of antifilarial treatment on HIV viral loads and
disease progression. This question is being addressed in a prospective, case-controlled study
of HIV/filarial coinfection.
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Figure 1.
A, Filarial antigen-positive sera in total number of sera positive for human immunodeficiency
virus (HIV) tested, by year. The gray bars represent percentages that were filarial antigen
positive within the total number of sera tested. B, Filarial antigen levels by detected by enzyme-
linked immunosorbent assay in HIV-negative and HIV-positive persons. The bar in the center
represents the median and each circle represents an individual patient.
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